Another four biotechs make Wall Street debut, raising $772M+ as IPO tidal wave crests
As four more biotechs go public Friday morning, the question must be asked — if a global pandemic can’t stop an IPO boom, can anything?
The tsunami continues with iTeos, Nurix, Annexon and Inozyme all making their trading debuts as the week comes to a close. iTeos and Nurix both priced at $19 per share, with each raising $201.1 million and $209 million, respectively. Annexon priced at $17 per share and raised $250.8 million, while Inozyme priced at $16 per share and raised $112 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.